JOURNAL BROWSE
Search
Advanced SearchSearch Tips
A Preliminary Study for Development of Clinical Practice Guidelines of Korean Medicine in Breast Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
A Preliminary Study for Development of Clinical Practice Guidelines of Korean Medicine in Breast Cancer
Lee, Kang-Wook; Yoo, Hwa-Seung; Lee, Jin-Sun; Lee, Nam-Hun;
  PDF(new window)
 Abstract
Objectives : The purpose of this study was to present the clinical practice guidelines for breast cancer through the analysis of existing clinical practice guidelines in Western and Chinese medicine. Methods : The literature search was performed regarding conventional and integrative medical treatment of breast cancer using Google Scholar, KIOM OASIS, PUBMED and Jisan library of Daejeon university. Results : Breast cancer is the fifth most common cancer in Korea. Recent studies revealed that combining conventional and integrative medical treatment can reduce the sequela of surgical operation and improve survival rate. However there isn’t still a systemic clinical guideline for breast cancer in korean medicine. This study will be a preliminary study to establish clinical practice guidelines of Korean Medicine for breast cancer.Conclusions : Further objective and systemic clinical studies related to Korean Medicine are needed to develope more advanced clinical practice guidelines of breast cancer.
 Keywords
breast cancer;Korean Medicine;clinical practice guidelines;
 Language
Korean
 Cited by
1.
A Case Study of a Patient with Breast Cancer Treated with a Combination of Traditional Korean Medicine and Chemotherapy, The Journal of Internal Korean Medicine, 2017, 38, 5, 820  crossref(new windwow)
 References
1.
National Cancer Information Center. Breast Cancer(cited Mar 1, 2016). Available from:URL:http://www.cancer.go.kr/mbs/cancer/index.jsp.

2.
Jung KH. Special Review: Personalized therapy for advanced breast cancer using molecular signatures. Korean Journal Med. 2009;77:26-34.

3.
Chen Z. Furenliangfangdaiquan. Seoul:Jungdam. 1993:71.

4.
Chao Y. Chaoshizhubingyuan-houlun. Seoul:Daesung. 1992:296.

5.
Zhang J. Jingyuequanshu. Shanghai :Shanghaikexuejishu. 1984:697.

6.
Li X, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. PLoS One. 2013;8(4):e60338. crossref(new window)

7.
Korea Breast Cancer Society. Korea Breast Cancer Society Practice Recommendations of Breast Cancer 2008(cited Mar 1, 2016). Available from:URL:http://guideline.or.kr/guideline/guide/contents.php?number=27&F_sid=660.

8.
National Comprehensive Cancer Network. NCCN Guidelines-Breast Cancer(cited Mar 1, 2016). Available from:URL:http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

9.
Lim HS. Guidelines for Diagnosis and Treatment of Malignant tumors in Chinese Medicine. Beijing:People’s Medical Publishing House. 2014:339-70.

10.
EKAT 2010. Evidence Reports of Kampo Treatment 2010, 345 Randomized Controlled Trials(cited Mar 1, 2016). Available from:URL:http://www.jsom.or.jp/medical/ebm/ere/pdf/EKATE2010.pdf.

11.
Jones A, et al. Pilot Feasibility Study to Assess the Utility of PET Scanning in the Pre-Operative Evaluation of Internal Mammary Nodes in Breast Cancer Patients Presenting with Medial Hemisphere Tumors. Clin Positron Imaging. 1991;2:331.

12.
Isasi CR, et al. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-12. crossref(new window)

13.
Cook GJ, et al. Detection of bone metastases in breast cancer by 18 FDG-PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-9. crossref(new window)

14.
Fisher B, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400-18. crossref(new window)

15.
Fisher B, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993-2000. crossref(new window)

16.
Cooke T, et al. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol. 2001;12:S23-S28. crossref(new window)

17.
American College of Radiology. Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma. J Am Coll Surg. 2007;205:362-76. crossref(new window)

18.
Hata T, et al. Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg. 2004;198:190-7. crossref(new window)

19.
Cheng JC, et al. Diagnostic thoracic computed tomography in radiotherapy for locoregional recurrent breast carcinoma. Int J Radiat Oncol Biol Phys. 1998;41:607-13. crossref(new window)

20.
Isasi CR, et al. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-12. crossref(new window)

21.
Cook GJ, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-9. crossref(new window)

22.
Edge SB, et al. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. New York: Springer. 2010:143.

23.
Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med. 1995;333:1444-55. crossref(new window)

24.
Arriagada R, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996;14:1558-64. crossref(new window)

25.
Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233-41. crossref(new window)

26.
Veronesi U, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227-32. crossref(new window)

27.
Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998;352:930-42. crossref(new window)

28.
Wood WC, et al. Dose and dose intensity of adjuvant chemotherapy for stageII, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-9. crossref(new window)

29.
Wolmark N, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.

30.
Rastogi P, et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocol B-18 and B-27. J Clin Oncol. 2008;26:778-85. crossref(new window)

31.
Aman U. Buzdar. Preoperative chemotherapy treatment of breast cancer-a review. Cancer. 2007;110:2394-407. crossref(new window)

32.
LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711-23. crossref(new window)

33.
Klijn JG, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343-53. crossref(new window)

34.
Hellman S. Stopping metastases at their source. N Engl J Med. 2007;337:996-7.

35.
Ragaz J, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956-62. crossref(new window)

36.
Ragaz J, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116-26. crossref(new window)

37.
Overgaard M, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949-55. crossref(new window)

38.
Overgaard M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet. 1999;353:1641-8. crossref(new window)

39.
Danish Breast Cancer Cooperative Group. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82b and c randomized studies. J Clin Oncol. 2006;24:2268-75. crossref(new window)

40.
Overgaard M, et al. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247-53. crossref(new window)